.jpg)
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso
J&J has the most convincing data that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line EGFR-mutated lung cancer—proof it could extend patients’ lives.
J&J has the most convincing data that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line EGFR-mutated lung cancer—proof it could extend patients’ lives.
